Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
The product is expected to be available in a week’s time
It plans to deliver over 300 million doses to the Indian government
DCGI approved the drug based on the review of clinical data
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
The company will market it under the brand name Molflu
The drug will be marketed under the brand name Molnaflu
The company has developed the API in house at its R&D center in Hyderabad
Subscribe To Our Newsletter & Stay Updated
